Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID06506149

A Prospective Evaluation of Microwave Ablation in the Treatment of Relapsed Graves' Disease

Led by The University of Hong Kong · Updated on 2024-07-29

25

Participants Needed

1

Research Sites

25 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating microwave ablation (MWA) as a minimally invasive treatment option for patients with relapsed Graves' disease who have previously been treated with anti-thyroid drugs but experienced a return of symptoms. Graves' disease is the most common cause of hyperthyroidism, and conventional treatments include anti-thyroid drugs, radioiodine, and surgery. However, these treatments have drawbacks such as side effects, risk of worsening eye symptoms, or surgical complications, which has led to interest in alternative therapies like MWA. In this study, all participants will receive ultrasound-guided MWA treatment using a device that inserts a microwave antenna into the thyroid gland to apply thermal energy and ablate the tissue. The procedure targets the entire thyroid gland, including both lobes, the isthmus, and the pyramidal lobe. This approach avoids surgical scars and preserves the organ, and it is performed as an outpatient procedure. The study does not involve comparison groups but focuses on evaluating this treatment. During the study, participants will be monitored for remission of Graves' disease six months after the procedure. Researchers will also measure changes in quality of life and thyroid gland volume at six months. The study includes follow-up assessments to evaluate treatment outcomes and safety. Participants can expect clinical evaluations and ultrasound examinations as part of their involvement. The total participation duration extends at least six months post-treatment.

CONDITIONS

Brief Title

A Prospective Evaluation of Microwave Ablation (MWA) in the Treatment of Relapsed Graves' Disease

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age older than 18 years
  • Relapsed Graves' disease after at least 18 months of anti-thyroid drug treatment
  • No vocal cord immobility
Not Eligible

You will not qualify if you...

  • Preference for or indication for surgery
  • Head or neck disease preventing neck hyperextension
  • History of thyroid cancer or malignant tumors in the neck region
  • History of neck irradiation
  • Severe Graves' ophthalmopathy
  • Large compressive goitre
  • Pregnancy or lactation
  • Contraindication to intravenous sedation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Implementation

Duration - 1 day

Participants receive ultrasound-guided microwave ablation treatment aimed at ablating the entire thyroid gland.

1 treatment visit (in-person)

Post-operative Follow-up

Duration - 6 months

Participants are monitored for changes in disease remission, quality of life, and thyroid volume after treatment.

Periodic follow-up visits over 6 months

Trial Site Locations

Total: 1 location

1

Queen Mary Hospital

Hong Kong, Hong Kong, 00000

Actively Recruiting

Loading map...

Research Team

Y

Yan Luk, MBBS

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Similar Trials

Ablation of Human Cardiac Fibrillation Based on Hierarchical...

Atrial Fibrillation (AF)

Actively Recruiting

1 location

The Efficacy and Safety of Allogenic Anti-CD19 CAR-T Cell Th...

Graves Disease

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

Two-year outcomes of single-session high-intensity focused ultrasound (HIFU) treatment in persistent or relapsed Graves' disease.

Brian Hung-Hin Lang, Yu-Cho Woo, Keith Wan-Hang Chiu

https://pubmed.ncbi.nlm.nih.gov/31209622

Single-Session High-Intensity Focused Ultrasound Treatment for Persistent or Relapsed Graves Disease: Preliminary Experience in a Prospective Study.

Brian Hung-Hin Lang, Yu-Cho Woo, Ian Yat-Hin Wong...

https://pubmed.ncbi.nlm.nih.gov/28727542

Efficacy of single-session radiofrequency ablation (RFA) in rendering euthyroidism for persistent/relapsed Graves' disease, a pilot study.

Man Him Matrix Fung, Brian Hung Hin Lang

https://pubmed.ncbi.nlm.nih.gov/37036479

Radiofrequency ablation and related ultrasound-guided ablation technologies for treatment of benign and malignant thyroid disease: An international multidisciplinary consensus statement of the American Head and Neck Society Endocrine Surgery Section with the Asia Pacific Society of Thyroid Surgery, Associazione Medici Endocrinologi, British Association of Endocrine and Thyroid Surgeons, European Thyroid Association, Italian Society of Endocrine Surgery Units, Korean Society of Thyroid Radiology, Latin American Thyroid Society, and Thyroid Nodules Therapies Association.

Lisa A Orloff, Julia E Noel, Brendan C Stack...

https://pubmed.ncbi.nlm.nih.gov/34939714

US-guided percutaneous microwave ablation for hyperthyroidism and immediate treatment response evaluation with contrast-enhanced ultrasound.

Jing-E Zhu, Hui-Li Zhang, Song-Yuan Yu...

https://pubmed.ncbi.nlm.nih.gov/34092625